Available Grant Opportunities


Week of Nov. 19th-28th, 2018

Check back often for weekly updates



Internal Funding Opportunities & Limited Submission Grants:


A. Alfred Taubman Medical Research Institute – Innovation Programs: Phenotyping in the Clinical Setting (Award amount variable, rolling deadline).  


The Taubman Institute is seeking to support new or existing teams of scientists to develop novel and impactful approaches to integrate their research programs into the clinic setting. The goal is to perform systematic, multiscale phenotyping to gain insights into individual variation in the susceptibility, progression, course, or outcomes of disease. The institute will partner with investigators to support the development and implementation of their research programs. This will include, but not be limited to, development of a research plan, identification of research partners within and external to U-M, infrastructure and database development, support for clinician and ancillary personnel in the clinic, clinical data collection, biological specimen collection, remote data collection, initiation of research plan, and data analysis. Our goal is to make every patient a research subject, and to define the genetic, environmental, behavioral and other components of individuals that contribute to their distinct emergent property related to health and disease. The goal is to also utilize the data to stratified an individual in order apply interventions that lead to the prevention, improved treatment, or cure of disease. The institute anticipates investing up to $2.5 million per year to support the funded projects. What are the criteria for funding? Impact on improving the lives of patients; Innovation in understanding the variability in onset or progression of disease, and reasons for differential response to treatment; Potential for future funding by the NIH or other external agencies; Potential for increased reimbursement for care by insurance companies, or cost savings to the medical system; and, Enhanced interactions with basic or other science disciplines (teams). Letter of intent:  Description of the proposed program. Who is going to work together and what will be their roles? Have you worked together in the past? Where do you want to perform this work? What infrastructure is needed to accomplish the goals? Who will you need to partner with to succeed? What are the present barriers to your success? What are your plans for downstream funding? Note: not all of these points must be addressed in the LOI. We seek to understand your vision for bringing science into the clinic. The main request here is for an outline of what you want to do and why it will be impactful. There is no deadline. Letters of intent are accepted on a rolling basis, and should be submitted to managing director Grace Wu (glwu@umich.edu). We encourage questions. You may contact us with written questions through Grace Wu (glwu@umich.edu). We’re happy to meet with individuals or teams to discuss ideas.


U-M Coulter Translational Research Partnership Program “Coulter Program” – 2019 Call for Proposals ($100,000+ award, Letter of Intent deadline February 4th, 2019). http://bme.umich.edu/research/coulter/  Have A Great Medical Innovation That Could Improve Patient Care?  The UM Coulter Translational Research Partnership Program “Coulter Program” is pleased to announce the 2019 Call for Proposals. The Coulter Program funds collaborative translational research projects between Engineering and Clinical faculty co-investigators. The goal of the program is to accelerate development and commercialization of new medical devices, diagnostics, and other medical product concepts that address unmet clinical needs and lead to improvements in healthcare. Projects are actively supported and mentored by Coulter Program Management and a team of industry-experienced experts who proactively work to accelerate Coulter Program objectives. Coulter Program objectives and metrics for success involve developing new product concepts to the point of partnering with industry or forming start-up companies with follow-on investor funding to commercialize new products envisioned from translational research efforts.  Coulter funding does not require a departmental funding match or cost-sharing of salaries. 4 – page proposal submissions. Distinctive aspects of the Coulter Program include business assessment work that dovetails with technical milestones for each project. Specific benefits to each project include: New product planning support; Business development support; Market research; Regulatory guidance; Follow-on funding guidance; Mentorship from the Oversight Committee; and, The C3i Commercialization Planning Program.  For more information, visit http://coulter.bme.umich.edu or download Coulter proposal instructions and application forms here: http://bme.umich.edu/research/coulter/process/apply/  For questions, please contact Thomas Marten, Managing Director, Coulter Program tmarten@umich.edu or (734) 647-1680. The program funds 5-7 projects per year for an average of over $100,000 each. The deadline for proposal submission is February 4, 2019.




Gray Foundation - Basser Initiative Team Science Grant Foundation ($5 million award, Letter of Intent deadline December 17th, 2018).  https://www.grayfoundation.org/team-science/

The mission of the Basser Initiative Team Science Grant Program is to fund highly meritorious research projects that bring together the best minds in cancer research to develop new therapies, prevention approaches, and better understanding of the fundamental mechanisms at play in BRCA-related cancers. The funded research projects will be multidisciplinary and, preferably, multi-institutional. The funding will be for a period of 3-5 years for a total of up to $3-5 million (up to $1 million/year).  LOI deadline: December 17, 2018, at 12:00 pm EST


Patient-Centered Outcomes Research Institute (PCORI):

  • Treatment of Anxiety in Children, Adolescents, and/or young Adults ($5 million, Letter of Intent deadline January 31st, 2019).  https://www.pcori.org/funding-opportunities/announcement/treatment-anxiety-children-adolescents-andor-young-adults-cycle-1 The Patient-Centered Outcomes Research Institute (PCORI) has had an ongoing interest in funding high-quality clinical studies that compare the effectiveness of evidence-based clinical strategies to treat anxiety disorders in children, adolescents, and/or young adults. PCORI intends to release a new funding announcement for this topic in January 2019. Clinical strategies to be studied may include pharmacological interventions, psychological interventions, or a combination of both. Each proposed comparator must be clearly defined, evidence-based, widely available, and appropriate for the age range and clinical severity of the study population. The proposed study population should include patients with a confirmed clinical diagnosis of a primary anxiety disorder and who are between 7 and 25 years of age. Applicants must clearly define the specific age range to be studied and provide a scientific rationale for the proposed study population and interventions. Applicants should consider several factors when defining their study population, including but not limited to: anxiety severity, type(s) of anxiety disorder(s), exposure to previous treatment(s)/treatment failure, recurrent or relapsed illness, and/or subpopulations.  Studies should be conducted in well-defined, primary, specialty and/or integrated clinical care settings where psychological services are consistent and well-characterized. Randomized controlled trials that compare the effectiveness of treatments are encouraged. Prospective, observational cohort studies that focus on assessing the heterogeneity of treatment effects and/or the comparative tolerability and safety of drugs may also be proposed. All studies should include outcome measures to assess function, symptoms, acceptability of treatment, and the measurement of adverse effects. Studies with a minimum follow-up period of nine months from baseline are sought, with one year of follow-up preferred. In addition, all studies funded through this initiative must include robust sample sizes of at least 300 participants, with sufficient power demonstrated to conduct the proposed analyses. The maximum project budget is $5 million in direct costs, with a maximum project duration of 3.5 years. Applicant Town Hall Session: January 22, 2019; 12:00 p.m. (ET). Letter of Intent (LOI) Deadline: January 31, 2019 by 5 p.m. (ET).


  • Treatment of Posttraumatic Stress Disorder in Adults ($5 million award, Letter of Intent deadline January 31st, 2019).  https://www.pcori.org/funding-opportunities/announcement/treatment-posttraumatic-stress-disorder-adults-cycle-1-2019Through this initiative, PCORI seeks to fund high-quality clinical studies that compare the effectiveness of evidence-based psychological and/or pharmacological treatments for posttraumatic stress disorder (PTSD) in adults. Previous research in PTSD has demonstrated the efficacy of many psychological interventions and some pharmacological treatments. However, few robust head-to-head, direct comparisons of evidence-based interventions have been completed to date. Studies that assess the heterogeneity of treatment effect within subgroups of interest (e.g., military versus civilian populations, men versus women, type of trauma, etc.) and those that include patients with comorbid conditions that frequently co-occur with PTSD (e.g., substance use disorder) are especially needed. The goal of this funding initiative is to support patient-centered comparative clinical effectiveness research to generate important findings about which specific treatments for adults with PTSD are most effective, and for whom. For this PFA, the proposed comparators may include psychological interventions, pharmacological interventions, or a combination of the two. All proposed comparators must have demonstrated evidence of efficacy (from systematic reviews, prior empirical investigations, or other scientific documentation). Study endpoints should include patient-centered outcomes, such as functional outcomes and quality of life, in addition to symptom-related measures. Studies must include a minimum of 6 months of follow-up. PCORI is especially interested in studies that are inclusive of a broad patient population, including those with comorbidities, and in studies that are powered to assess the effectiveness of treatments in subgroups of interest. The maximum project budget is $5 million in direct costs, with a maximum project duration of 3.5 years (42 months). Letter of Intent (LOI) Deadline: January 31, 2019 by 5 p.m. (ET).


  • Treatment Options for Age-Related Hearing Loss ($2 million award, deadline January 31st, 2019).  https://www.pcori.org/funding-opportunities/announcement/treatment-options-age-related-hearing-loss-cycle-1-2019 This PCORI funding announcement (PFA) invites applications for high-quality comparative effectiveness research (CER) projects that focus on treatment options for adults 50 years or older with mild to moderate age-related hearing loss or presbycusis. For this PFA, investigators should address important decisional dilemmas by comparing treatment options that may include hearing devices and/or the support service models accompanying these devices. Hearing devices may encompass, but are not limited to, hearing aids or personal sound amplification products. Examples of support service models include audiologist or licensed technician fitting of hearing aids, patient self-selection and fitting of hearing aids, and counseling or education interventions. Proposed comparators must have established evidence of efficacy for hearing-related outcomes or widespread use. PCORI solicits the submission of applications that propose rigorous randomized controlled trials or observational prospective cohort studies that evaluate the comparative effectiveness of hearing loss interventions on important patient-centered outcomes such as hearing-specific health-related quality of life or psychosocial outcomes as well as relevant functional outcomes for device comparisons for up to 6 months. Please note that PCORI does not fund intervention costs and investigators will be required to document how they plan to cover these costs. Investigators may request up to $2 million in direct costs for each project and a maximum study duration of three years. Studies with well justified design and analysis plans that may be completed in a shorter time frame are encouraged. Letter of Intent (LOI) Deadline: January 31, 2019 by 5 p.m. (ET).


SWOG/Hope Foundation:

  • Impact Award 2019 Announcement ($250,000 award, two funding cycle Letter of Intent deadlines January 15th and July 1st, 2019).  https://thehopefoundation.org/research-funding/juried-programs/swog-hope-foundation-impact-award/ The SWOG/Hope Foundation Impact Award is a funding program from The Hope Foundation that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to clinical trials in SWOG and the NCTN in the foreseeable future. Funding for smaller feasibility projects that are critical to the conduct of future SWOG trials are also encouraged. Objectives: Achieving SWOG’s mission of changing the practice of cancer medicine in clinical trials requires innovative ideas, techniques and perspectives. SWOG and The Hope Foundation understand that novel ideas might not align with current thinking or may not yet be supported by substantial preliminary data. The Impact Award Program is intended to foster novel scientific ideas, agents, targets, and technologies that have the potential to substantially advance the practice of clinical cancer research within the Group. For example, a project may seek to identify new predictive bio-markers for prevention, supportive care or therapeutic studies, assess the feasibility of an agent device or measurement tool, identify resistance mechanisms, develop new technologies for monitoring therapeutic response, or develop and test novel methodologies to assist with the conduct of health care delivery studies. These studies may involve considerable scientific risk but may potentially lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research. It is expected that support via this mechanism will lead to subsequent extramural support from other sources and will be a metric of success for this grant awarding program. In addition, publications citing SWOG and The Hope Foundation will be further metrics for success of the program. Individual projects are funded for up to $250,000 (total cost) and may be spent over a 1 - or 2-year award period. LOI Deadlines: January 15 and July 1 at 5pm ET.


  • 2019 SWOG Career Engagement Award – A Program for Mid-Career Investigators ($100,000 award, deadline March 1st, 2019).  https://thehopefoundation.org/research-funding/juried-programs/career-engagement/ Career Engagement Awards are intended to ensure protected time for mid-career investigators from SWOG-affiliated institutions to pursue clinical research initiatives. SWOG Member Institutions may nominate multiple candidates, as appropriate. 2-year fellowships of $50,000/year are provided as salary support ensuring that investigators’ time is protected for research in the clinic or laboratory. The deadline is 5pm ET on March 1, 2019.


Parkinson’s Foundation – Clinical Research Award ($200,000 award, Letter of Intent deadline January 22nd, 2019).  http://www.parkinson.org/research/Grant-Opportunities/clinical-research-awards?_ga=2.89078802.847267126.1543330269-1537955967.1526554928  Clinician scientists are key experts who are vital to research involving those living with Parkinson’s disease. They bring lessons learned from the bedside to the bench, and from the bench to the bedside. Despite the projected increase in the number of people with Parkinson’s disease, there remains a shortage of those trained in the clinical research process necessary to advance therapies forward to benefit people living with PD. Therefore, the Parkinson’s Foundation is sponsoring a research award intended to facilitate the development of clinician scientists. This two-year award supports the research expenses of a clinician scientist whose clinically oriented research involves people living with Parkinson’s disease. Clinician scientists of all stages (from fellows to established faculty) may apply but preference will be given to the support of junior investigators. Level of Support: The Parkinson’s Foundation Clinical Research Award is for $200,000 total over two years.


March of Dimes – Call for Nominations: March of Dimes and Richard B. Johnston, Jr., MD Prize in Developmental Biology ($150,000 award, deadline January 7th, 2019). https://www.marchofdimes.org/research/prize-in-developmental-biology.aspx The March of Dimes and Richard B. Johnston, Jr., MD Prize in Developmental Biology honors an outstanding scientist(s) who has profoundly advanced the science that underlies our understanding of pregnancy, parturition and prenatal development. Nominations are solicited for the 2019 annual March of Dimes and Richard B. Johnston, Jr., MD Prize in Developmental Biology.  Nominees should be scientific leaders who have pioneered research to advance our understanding of prenatal development and pregnancy. The Prize carries a cash award of $150,000 and a silver medal in the design of a Roosevelt dime, to commemorate of our founder, President Franklin D. Roosevelt.


RIAT Restoring Invisible & Abandoned Trials) Support Center ($150,000 award, deadline April 15th, 2019).  https://restoringtrials.org/grants/ The RIAT (Restoring Invisible & Abandoned Trials) Support Center will administer grant competitions, making awards to third-party researchers wishing to correct a misreported trial or publish a completed trial that remains unpublished. Over the course of 2018-2020, the RIAT Support Center will be holding multiple funding competitions. The Laura and John Arnold Foundation has provided the funding for the competitions, but has no involvement in the determination of the winners selected.  There are 2 core categories of projects funded through RIAT. Projects applicable to either RIAT category are eligible: Misreported Trial Restorations: These projects apply to already published trials for which existing evidence indicates errors, omissions, or inaccuracies in published methods, findings, or conclusions. Unpublished Trial Restorations:  These projects apply to trials that were carried out, completed, and remain unpublished. Judging/Review Criteria:

Need: Have the applicants demonstrated the need for restoration of this trial through RIAT? Data: Have the applicants demonstrated access to sufficient data to complete the restoration? Impact: What is the potential impact of the proposed RIAT on healthcare and science? Restoration Team: Do the applicants have the expertise and resources required to successfully complete the proposed restoration? Cost: Is the budget justified for the planned scope of work? Expression of Interest: Please let us know if you are thinking of applying. Email support@restoringtrials.org.  This step is optional, but will help us with our planning. Thanks! Individual Grant Amount: up to $150,000 USD, depending on nature of project. Submission deadline: 11:59pm Eastern Standard Time on April 15th, 2019, via Submittable


AACR & AstraZeneca – Ovarian Cancer Research Fellowship ($120,000 award, deadline January 17th, 2019).  https://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=58

The AACR-AstraZeneca Ovarian Cancer Research Fellowships represent a joint effort to encourage and support postdoctoral or clinical research fellows to conduct ovarian cancer research and to establish a successful career path in this field. The research proposed for funding must have direct applicability to ovarian cancer with a specific focus on DNA damage repair pathways and may be basic, translational, clinical, or epidemiological in nature. Any proposals that address topics unrelated to DNA damage repair pathways in ovarian cancer will NOT be accepted.

This fellowship provides a two-year grant of $120,000 to support the salary and benefits of the fellow while working on a mentored ovarian cancer research project. AACR requires applicants to submit an electronic application by 1:00pm, U.S. Eastern Time on Thursday, January 17, 2019, using the proposalCENTRAL website at https://proposalcentral.altum.com.


Citizens united for Research in Epilepsy (CURE) – Taking Flight Award – Promoting the Careers of Young Investigators ($100,000 award, Letter of Intent deadline January 8th, 2019). https://www.cureepilepsy.org/grants-program/#grant_opportunities CURE seeks to promote the careers of young investigators to allow them to develop a research focus independent of their mentor(s).  Researchers may propose basic or clinical studies, but this award mechanism is not intended to support clinical trials. Research that involves collaboration and a multidisciplinary approach is desirable. Applicant will be required to discuss how this avenue of research is independent from his or her mentor’s research and will lead him or her to a path of independent epilepsy research. We encourage studies that will provide new directions for epilepsy therapy, prevention and, ultimately, a cure and that will allow applicants to collect the data necessary to support grant application to the National Institutes of Health or similar granting agency.  Requests may be made for up to $100,000 for one year.  Letter of Intent Deadline: Tuesday, January 8th, 2019 – 9pm ET.